Controlled Therapy Interruption Improves Host Immune Control of Chronic Hepatitis B Virus Infection in HBeAg-Positive Patients.
Prolonged viral suppression with oral antiviral drugs allows partial immune reconstitution. Controlled therapy interruption (CTI), by leveraging secondary immune response, proposes further augmentation in chronic hepatitis B virus (HBV) infection. Transient treatment interruptions (TIs) at months 0, 1, and 3 during otherwise continuous oral antiviral therapy allow viremic bursts, simulating autovaccination. Four weekly injections of Hepatitis B Immunoglobulin are given before the second and third TI to simulate prime boosting, which specifically amplifies the immune response. Fourteen patients (10 males; four controls, four HBeAg positive, and six anti-HBe positive) aged 28-46 years were studied. The period between TI and reappearance of viremia, time to relapse (TTR) (weeks) estimated immune control. The other endpoints included reduction in serum HBsAg IU/mL and loss of HBeAg. TTR after the first TI was significantly shorter in HBeAg-positive patients, indicating low baseline immunity. TTR increased significantly after the second and subsequent TI in all four HBeAg-positive patients. One patient persistently lost HBeAg. Mean HBsAg levels fell significantly in three of four patients after the second TI. In contrast, in the anti-HBe-positive group, TTR was unchanged after all three TI. Furthermore, no significant changes in HBsAg levels were detected after the second or subsequent TIs. No significant differences in adverse events were noted between groups. HBeAg-positive patients have low baseline levels of host immune control against HBV. CTI consistently boosts this immunity. CTI did not influence immunity in anti-HBe-positive patients.
Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School , Boston, Massachusetts.
Gerond V
GV
Lake-Bakaar
Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School , Boston, Massachusetts.
Daryl
D
Lau
Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School , Boston, Massachusetts.
Ping-Ping
PP
Kuang
Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School , Boston, Massachusetts.
Kiran
K
Singh
D000328:Adult; D000998:Antiviral Agents / Q000008:administration & dosage*; D004358:Drug Therapy / Q000379:methods; D005260:Female; D006513:Hepatitis B e Antigens / Q000097:blood*; D019694:Hepatitis B, Chronic / Q000188:drug therapy* / Q000276:immunology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome; D028761:Withholding Treatment
D000998:Antiviral Agents; D006513:Hepatitis B e Antigens